Comparison of Effectiveness of Gefitinib, Erlotinib, and Afatinib in Advanced Non-small Cell Lung Cancer Patients with EGFR Mutation Positive in Indonesian Population

Comparison of Effectiveness of Gefitinib, Erlotinib, and Afatinib in Advanced Non-small Cell Lung Cancer Patients with EGFR Mutation Positive in Indonesian Population

Background and objective EGFR-tyrosine kinase inhibitors (EGFR-TKIs) were used to treat non-small cell lung cancer (NSCLC) patients with EGFR mutation positive. This study aims to compare the effectiveness of first line TKIs; gefitinib, erlotinib, and afatinib in the treatment of advanced stage NSCL...

Full description

Bibliographic Details
Main Authors: Noorwati SUTANDYO, Arif HANAFI, Mulawarman JAYUSMAN
Format: Article
Language:zho
Published: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2019-09-01
Series:Chinese Journal of Lung Cancer
Subjects:
Lung neoplasms
EGFR mutation positive
Tyrosine kinase inhibitors
Online Access:http://dx.doi.org/10.3779/j.issn.1009-3419.2019.09.02

Internet

http://dx.doi.org/10.3779/j.issn.1009-3419.2019.09.02

Similar Items